Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Long-term, Prospective, Non-interventional, Extension of a Phase III, Randomized, Placebo-controlled, Multicenter Study to Assess the Safety & Efficacy of Engensis (VM202) in Subjects With Painful Diabetic Peripheral Neuropathy

Next Previous
Search
Trial Profile

Long-term, Prospective, Non-interventional, Extension of a Phase III, Randomized, Placebo-controlled, Multicenter Study to Assess the Safety & Efficacy of Engensis (VM202) in Subjects With Painful Diabetic Peripheral Neuropathy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Donaperminogene seltoplasmid (Primary)
  • Indications Diabetic neuropathies; Neuropathic pain
  • Focus Adverse reactions; Registrational
  • Sponsors Helixmith

    • Most Recent Events

    • 14 Mar 2022 Results published in the Helixmith Media Release.
    • 14 Mar 2022 According to a Helixmith media release, the paper reporting results from the trial was one of the top-10 most-downloaded articles in Clinical and Translational Science (CTS) in 2021. CTS is the official publication of the American Society for Clinical Pharmacology & Therapeutics (ASCPT).
    • 14 Mar 2022 According to a Helixmith media release, results from the study were published in Clinical and Translational Science (CTS) in 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top